[go: up one dir, main page]

WO2018151840A3 - Méthodes et compositions de traitement de tumeurs malignes - Google Patents

Méthodes et compositions de traitement de tumeurs malignes Download PDF

Info

Publication number
WO2018151840A3
WO2018151840A3 PCT/US2018/000054 US2018000054W WO2018151840A3 WO 2018151840 A3 WO2018151840 A3 WO 2018151840A3 US 2018000054 W US2018000054 W US 2018000054W WO 2018151840 A3 WO2018151840 A3 WO 2018151840A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
mammal
methods
malignant tumors
kras
Prior art date
Application number
PCT/US2018/000054
Other languages
English (en)
Other versions
WO2018151840A2 (fr
Inventor
Wenbin Ying
Kenjirou Minomi
Jihua Liu
Li Wang
Bharat Majeti
Roger Adami
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/434,318 external-priority patent/US10792299B2/en
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Priority to JP2018535394A priority Critical patent/JP2019508379A/ja
Publication of WO2018151840A2 publication Critical patent/WO2018151840A2/fr
Publication of WO2018151840A3 publication Critical patent/WO2018151840A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des méthodes et des compositions permettant de prévenir, de traiter ou d'atténuer un ou plusieurs symptômes d'une tumeur maligne associée à une mutation de KRAS chez un mammifère en ayant besoin, par identification d'une cellule tumorale chez ledit mammifère, la cellule tumorale étant caractérisée par au moins : (i) une mutation du gène KRAS, et/ou (ii) un niveau d'expression aberrant de la protéine KRAS ; et administration audit mammifère d'une quantité thérapeutiquement efficace d'une composition comprenant une ou plusieurs molécules d'ARNi qui sont actives pour réduire l'expression de la GST-π.
PCT/US2018/000054 2017-02-16 2018-02-16 Méthodes et compositions de traitement de tumeurs malignes Ceased WO2018151840A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018535394A JP2019508379A (ja) 2017-02-16 2018-02-16 悪性腫瘍に対する治療方法及び治療用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/434,318 US10792299B2 (en) 2014-12-26 2017-02-16 Methods and compositions for treating malignant tumors associated with kras mutation
US15/434,318 2017-02-16

Publications (2)

Publication Number Publication Date
WO2018151840A2 WO2018151840A2 (fr) 2018-08-23
WO2018151840A3 true WO2018151840A3 (fr) 2018-10-11

Family

ID=63170424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/000054 Ceased WO2018151840A2 (fr) 2017-02-16 2018-02-16 Méthodes et compositions de traitement de tumeurs malignes

Country Status (2)

Country Link
JP (2) JP2019508379A (fr)
WO (1) WO2018151840A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046480A1 (fr) * 2019-09-06 2021-03-11 The Regents Of The University Of California Administration d'agents thérapeutiques à médiation par acide nucléique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160186183A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007051303A1 (fr) * 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. Molecules d'arnsi modifiees et utilisations de celles-ci
WO2007134161A2 (fr) * 2006-05-11 2007-11-22 Alnylam Pharmaceuticals, Inc. Compositions et procédés d'inhibition de l'expression du gène pcsk9
AU2008270209B2 (en) * 2007-07-05 2012-05-17 Arrowhead Pharmaceuticals, Inc. dsRNA for treating viral infection
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
JP6899201B2 (ja) * 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160186183A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20160186182A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Rna interference compositions and methods for malignant tumors

Also Published As

Publication number Publication date
JP2019508379A (ja) 2019-03-28
JP2019033741A (ja) 2019-03-07
WO2018151840A2 (fr) 2018-08-23

Similar Documents

Publication Publication Date Title
WO2016106404A3 (fr) Méthodes et compositions destinées à traiter les tumeurs malignes associées à une mutation de kras
NZ763275A (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
WO2019006418A3 (fr) Vecteurs viraux adéno-associés destinés à la thérapie génique
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
WO2018140920A8 (fr) Compositions et méthodes d'inhibition de l'expression génique du facteur xii
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EP4393495A3 (fr) Compositions d'arni de ligand 1 de mort cellulaire programmée 1 (pd-l1) et leurs procédés d'utilisation
WO2018098117A8 (fr) Compositions à base d'arni ciblant le gène serpina1 et leurs méthodes d'utilisation
WO2021096763A8 (fr) Procédés et compositions pour le traitement d'un trouble associé à l'angiotensinogène (agt)
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
BR112016028641A2 (pt) ?método para tratar câncer?
BR112023022481A2 (pt) Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica
WO2020072126A3 (fr) Modulation de ptpn2 pour accroître les réponses immunitaires et perturber l'expression génique dans des lignées de cellules souches hématopoïétiques
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
WO2020146521A3 (fr) Agents d'arni pour inhiber l'expression de hif-2 alpha (epas1), leurs compositions et méthodes d'utilisation
IN2014DN08199A (fr)
EP4410373A3 (fr) Acide nucléique inhibant simultanément l'expression du gène mtor et du gène stat3
MX379585B (es) Composición para usarse en el tratamiento de cáncer que presenta pérdida hemicigota de tp53.
WO2023081500A3 (fr) Conjugués oligonucleotides/arni
BR112014016723A2 (pt) método para o tratamento de câncer de mama
MX2022004524A (es) Tratamiento génico para la enfermedad de alzheimer.
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer
WO2019075216A8 (fr) Anticorps se liant à la plectine-1 et utilisations associées

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018535394

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18754969

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18754969

Country of ref document: EP

Kind code of ref document: A2